Development of Potent and Selective PfCLK3 Inhibitors Based on GSK-TCMDC151 as a New Class of Antimalarials
doi 10.26434/chemrxiv.9817202.v1
Full Text
Open PDFAbstract
Available in full text
Date
September 13, 2019
Authors
Publisher
American Chemical Society (ACS)